fritz Offner
Universiteit Gent
H-index: 62
Europe-Belgium
Top articles of fritz Offner
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Blood
2024/1/11
Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging
Insights into Imaging
2024/4/10
Fritz Offner
H-Index: 38
Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up
Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
2024/2/1
COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA
Hematological Oncology
2023/6
Metabolic response rates of epcoritamab+ R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma …
2023/6/1
Phase I study of safety and pharmacokinetics of RO7297089, an anti-BCMA/CD16a bispecific antibody, in patients with relapsed, refractory multiple myeloma
Clinical Hematology International
2023/3
Cindy Lee
H-Index: 32
Michel Delforge
H-Index: 40
Fritz Offner
H-Index: 38
Junyi Li
H-Index: 7
Karen Miller
H-Index: 48
RNA extraction method impacts quality metrics and sequencing results in formalin-fixed, paraffin-embedded tissue samples
Laboratory Investigation
2023/2/1
Kimberly Verniers
H-Index: 3
Fritz Offner
H-Index: 38
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study
EClinicalMedicine
2023/2/1
Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen induced exhaustion
bioRxiv
2023/1/22
Systemic mastocytosis with myeloid sarcoma and B-CLL: molecular and clonal heterogeneity in a rare case of SM-AHN with review of literature
2023/1/2
Fritz Offner
H-Index: 38
Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation …
Blood
2023/11/28
Real-World Effectiveness and Safety of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) in Belgium after 4 Years
Blood
2023/11/28
Fritz Offner
H-Index: 38
Subcutaneous Epcoritamab With R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated Results From EPCORE NHL-2
2023
Fritz Offner
H-Index: 38
Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed/Refractory Mantle Cell Lymphoma
2023
Michael Dickinson
H-Index: 1
Fritz Offner
H-Index: 38
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial
EJHaem
2023/11
Fritz Offner
H-Index: 38
Hirohiko Shibayama
H-Index: 19
Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 1b/2 EPCORE CLL-1 trial expansion cohort
2023
Fritz Offner
H-Index: 38
Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid …
Frontiers in oncology
2023/10/25
Kimberly Verniers
H-Index: 3
Fritz Offner
H-Index: 38
MCL-467 glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma
Clinical Lymphoma Myeloma and Leukemia
2023/9/1
Michael Dickinson
H-Index: 1
Fritz Offner
H-Index: 38
Long-term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) With Relapsed/Refractory (r/r) Follicular Lymphoma (FL) Treated With Tisagenlecleucel in the …
2023
Ai Chen
H-Index: 4
Fritz Offner
H-Index: 38
CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)
Clinical Lymphoma Myeloma and Leukemia
2023/9/1
